Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

An Antibody Designed to Improve Adoptive NK-Cell Therapy Inhibits Pancreatic Cancer Progression in a Murine Model.

Lee J, Kang TH, Yoo W, Choi H, Jo S, Kong K, Lee SR, Kim SU, Kim JS, Cho D, Kim J, Kim JY, Kwon ES, Kim S.

Cancer Immunol Res. 2019 Feb;7(2):219-229. doi: 10.1158/2326-6066.CIR-18-0317. Epub 2018 Dec 4.

PMID:
30514792
2.

Autologous Immune Enhancement Therapy for Cancer - Our experience since 2004.

Terunuma H.

J Stem Cells Regen Med. 2012 Nov 26;8(3):205-6. eCollection 2012.

PMID:
24693200
3.

CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo.

Wennerberg E, Kremer V, Childs R, Lundqvist A.

Cancer Immunol Immunother. 2015 Feb;64(2):225-35. doi: 10.1007/s00262-014-1629-5. Epub 2014 Oct 26.

PMID:
25344904
4.

Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.

Chalabi-Dchar M, Cassant-Sourdy S, Duluc C, Fanjul M, Lulka H, Samain R, Roche C, Breibach F, Delisle MB, Poupot M, Dufresne M, Shimaoka T, Yonehara S, Mathonnet M, Pyronnet S, Bousquet C.

Gastroenterology. 2015 Jun;148(7):1452-65. doi: 10.1053/j.gastro.2015.02.009. Epub 2015 Feb 13.

PMID:
25683115
5.

Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.

Kremer V, Ligtenberg MA, Zendehdel R, Seitz C, Duivenvoorden A, Wennerberg E, Colón E, Scherman-Plogell AH, Lundqvist A.

J Immunother Cancer. 2017 Sep 19;5(1):73. doi: 10.1186/s40425-017-0275-9. Erratum in: J Immunother Cancer. 2017 Nov 6;5(1):88.

6.

Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.

Ferreira-Teixeira M, Paiva-Oliveira D, Parada B, Alves V, Sousa V, Chijioke O, Münz C, Reis F, Rodrigues-Santos P, Gomes C.

BMC Med. 2016 Oct 21;14(1):163.

7.

IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.

McMichael EL, Jaime-Ramirez AC, Guenterberg KD, Luedke E, Atwal LS, Campbell AR, Hu Z, Tatum AS, Kondadasula SV, Mo X, Tridandapani S, Bloomston M, Ellison EC, Williams TM, Bekaii-Saab T, Carson WE 3rd.

Clin Cancer Res. 2017 Jan 15;23(2):489-502. doi: 10.1158/1078-0432.CCR-16-0004. Epub 2016 Jul 19.

8.

Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells.

Gürlevik E, Fleischmann-Mundt B, Brooks J, Demir IE, Steiger K, Ribback S, Yevsa T, Woller N, Kloos A, Ostroumov D, Armbrecht N, Manns MP, Dombrowski F, Saborowski M, Kleine M, Wirth TC, Oettle H, Ceyhan GO, Esposito I, Calvisi DF, Kubicka S, Kühnel F.

Gastroenterology. 2016 Aug;151(2):338-350.e7. doi: 10.1053/j.gastro.2016.05.004. Epub 2016 May 20.

PMID:
27210037
9.

Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.

Shi S, Wang R, Chen Y, Song H, Chen L, Huang G.

PLoS One. 2013 Jun 14;8(6):e65757. doi: 10.1371/journal.pone.0065757. Print 2013.

10.

Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.

Schettini J, Kidiyoor A, Besmer DM, Tinder TL, Roy LD, Lustgarten J, Gendler SJ, Mukherjee P.

Cancer Immunol Immunother. 2012 Nov;61(11):2055-65. doi: 10.1007/s00262-012-1264-y. Epub 2012 Apr 28.

11.

Immune responsiveness in a mouse model of combined adoptive immunotherapy with NK and dendritic cells.

Cui F, Ji J, Lv H, Qu D, Yu C, Yang Y, Xu Y.

J Cancer Res Ther. 2013 Nov;9 Suppl:S162-8. doi: 10.4103/0973-1482.122516.

12.

NK cells shape pancreatic and oral tumor microenvironments; role in inhibition of tumor growth and metastasis.

Jewett A, Kos J, Fong Y, Ko MW, Safaei T, Perišić Nanut M, Kaur K.

Semin Cancer Biol. 2018 Dec;53:178-188. doi: 10.1016/j.semcancer.2018.08.001. Epub 2018 Aug 3. Review.

PMID:
30081230
13.

Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.

Hokland M, Kjaergaard J, Kuppen PJ, Nannmark U, Agger R, Hokland P, Basse P.

In Vivo. 1999 May-Jun;13(3):199-204.

PMID:
10459491
15.

Isolation and (111)In-Oxine Labeling of Murine NK Cells for Assessment of Cell Trafficking in Orthotopic Lung Tumor Model.

Malviya G, Nayak T, Gerdes C, Dierckx RA, Signore A, de Vries EF.

Mol Pharm. 2016 Apr 4;13(4):1329-38. doi: 10.1021/acs.molpharmaceut.5b00947. Epub 2016 Mar 24.

PMID:
26962716
16.

Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice.

Castriconi R, Dondero A, Cilli M, Ognio E, Pezzolo A, De Giovanni B, Gambini C, Pistoia V, Moretta L, Moretta A, Corrias MV.

Cancer Immunol Immunother. 2007 Nov;56(11):1733-42. Epub 2007 Apr 11.

PMID:
17426969
17.

Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.

Brooks J, Fleischmann-Mundt B, Woller N, Niemann J, Ribback S, Peters K, Demir IE, Armbrecht N, Ceyhan GO, Manns MP, Wirth TC, Kubicka S, Bernhardt G, Smyth MJ, Calvisi DF, Gürlevik E, Kühnel F.

Cancer Res. 2018 Jan 15;78(2):475-488. doi: 10.1158/0008-5472.CAN-17-2415. Epub 2017 Nov 27.

18.

Anergic natural killer cells educated by tumor cells are associated with a poor prognosis in patients with advanced pancreatic ductal adenocarcinoma.

Yang C, Cheng H, Zhang Y, Fan K, Luo G, Fan Z, Huang Q, Lu Y, Jin K, Wang Z, Yu X, Liu C.

Cancer Immunol Immunother. 2018 Dec;67(12):1815-1823. doi: 10.1007/s00262-018-2235-8. Epub 2018 Aug 22.

PMID:
30167864
19.

Successful adoptive immunotherapy with OK432-inducible activated natural killer cells in tumor-bearing mice.

Yamaue H, Tanimura H, Iwahashi M, Tsunoda T, Tani M, Inoue M.

Biotherapy. 1990;2(1):51-61.

PMID:
2400628
20.

Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction.

Peng YP, Zhang JJ, Liang WB, Tu M, Lu ZP, Wei JS, Jiang KR, Gao WT, Wu JL, Xu ZK, Miao Y, Zhu Y.

BMC Cancer. 2014 Oct 2;14:738. doi: 10.1186/1471-2407-14-738.

Supplemental Content

Support Center